Costs associated with adverse events for systemic therapies in metastatic melanoma. (7th September 2018)

• Record Type: Journal Article
• Authors: Fu, Alex Z; Li, Zhiyi; Tang, Jackson; Mahmood, Syed; Whisman, Tyler; Qiu, Ying
• Is Part Of: Journal of comparative effectiveness research. Volume 7:Number 9(2018)
• Page Start: 867
• Page End: 879
• Publication Date: 2018-09-07
• Subjects: adverse events -- chemotherapy -- cost -- immunotherapy -- metastatic melanoma -- targeted therapy; Medical care -- Research -- Periodicals; Medical care -- Research -- Evaluation -- Periodicals; Medical care -- Decision making -- Periodicals; Evidence-based medicine -- Periodicals; Medicine, Comparative -- Periodicals; 362.1072
• DOI: 10.2217/cer-2018-0022
• Languages: English
• ISSNs: 2042-6305

Abstract

Aim: To determine the costs of adverse events (AEs) associated with current metastatic melanoma (MM) therapies.Materials & methods: Two retrospective cohort studies were independently conducted using the PharMetrics and MarketScan databases. Included patients were aged ≥18 years, and had ≥1 MM diagnosis and ≥1 claim for systemic therapy from 2004 to 2015.Results: A total of 1654 and 1329 patients were identified in PharMetrics and MarketScan, respectively. The corresponding adjusted 30-day incremental costs of AEs by category were highest for CNS/psychiatric (US$21, 277 and $18, 739), gastrointestinal ($18, 534 and $15, 648), respiratory ($17, 338 and $17, 064), cardiovascular ($16, 083 and $15, 430), hematological/lymphatic ($14, 997 and $15, 538) and metabolic/nutritional AEs ($12, 340 and $17, 251).Conclusion: The costs of AEs associated with systemic therapies for MM are substantial.